Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALPINE trial
2023-504696-24-00Phase 2Authorised
- Sponsor
- Erasmus MC
- Start
- Jul 2023
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 2
01
Overview
Phase 2, single-arm trial of lutetium Lu 177 PSMA I&T in diffuse astrocytoma, Oligodendroglioma (OG) and glioblastoma (GBM), sponsored by Erasmus MC. Planned start Jul 2023; status: authorised.
02
Drugs
lutetium Lu 177 PSMA I&T
03
Conditions
diffuse astrocytomaOligodendroglioma (OG)glioblastoma (GBM)
Beyond the preview
Go deeper on 2023-504696-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504696-24-00.